ライフサイエンスコーパス: syncope

1 inued treatment because of an adverse event (syncope).

2 on [AF], and 4% with a history of arrhythmic syncope).

3 haemorrhage, severe anaemia, and cardiogenic syncope).

4 or cardiac failure, atrial fibrillation, and syncope).

5 ina, non-ST-elevation myocardial infarction, syncope).

6 rliest BP decrease occurred 9 minutes before syncope.

7 ity, and the remaining 6 addressed vasovagal syncope.

8 es among adult patients with reflex-mediated syncope.

9 ruction and symptoms of dyspnea, angina, and syncope.

10 lude dyspnoea, chest pain, palpitations, and syncope.

11 in patients with cardioinhibitory vasovagal syncope.

12 A 45-year-old woman presented with syncope.

13 patients hospitalized for a first episode of syncope.

14 outcome measure was the first recurrence of syncope.

15 but without postural lightheadedness or near syncope.

16 being on fludrocortisone prevents vasovagal syncope.

17 class, Canadian Cardiology Society class, or syncope.

18 there were alternative explanations for the syncope.

19 se neurological symptoms such as vertigo and syncope.

20 ystole>6 s is strongly associated with ictal syncope.

21 ed palpitations, 47% fatigue, and 30% (near-)syncope.

22 ic information for emergency department (ED) syncope.

23 rare, serious, and often treatable cause of syncope.

24 ictal asystole episodes, 15 of which led to syncope.

25 ricular failure with shortness of breath and syncope.

26 eactions (6 were hypotensive) and 6 reported syncope.

27 ode of aborted sudden death, and 8 (20%) had syncope.

28 table cardioverter defibrillator shocks, and syncope.

29 unaltered (placebo) followed by LBNP to pre-syncope.

30 a future role in the management of falls and syncope.

31 abdominal pains, breathing difficulties, and syncope.

32 ty, with no apparent increase in the risk of syncope.

33 d ventricular tachycardia, or arrhythmogenic syncope.

34 tween 2006 and 2012 for diagnostic workup of syncope.

35 apy, and the use of pacemakers for vasovagal syncope.

36 tients at a median time of 58 seconds before syncope.

37 ts without previous comorbidity admitted for syncope.

38 tifies AS patients with an increased risk of syncope.

39 lization, device implantation, and recurrent syncope.

40 ed from subclinical to occasional exertional syncope.

41 lack race, intramural course, and exertional syncope.

42 associated with lower likelihood of cardiac syncope.

43 y identify patients with and without cardiac syncope.

44 in hypothesis of the physiology of vasovagal syncope.

45 d prognostic information in ED patients with syncope.

46 nd GG males had 9% versus 77% likelihoods of syncope.

47 sible gene variants associate with vasovagal syncope.

48 e broad spectrum of patients presenting with syncope.

49 ermine the prevalence of PE in patients with syncope.

50 ssociated with greater likelihood of cardiac syncope.

51 chycardia [6], near-drowning [2], exertional syncope [1], symptoms on therapy [2], LQT3 [1], QTc>520

52 luding non-specific chest pain, dyspnoea and syncope (1368 [6%] deaths), and respiratory disorders (2

53 capture after implantation: 1 has recurrent syncope, 2 eventually died.

54 The end point consisted of (1) syncope, (2) symptomatic presyncopal episodes associated

55 ed ventricular tachycardia; or aborted SCD), syncope, 24-hour premature ventricular complexes count,

56 al fibrillation 58 (70%) or neurocardiogenic syncope 25 (30%), New York Heart Association class<II an

57 and 28.9% for controls; P=0.045), presyncope/syncope (27.8% for cases and 21.3% for controls; P<0.001

58 ly different between groups in time to first syncope: 29.2 months (95% CI: 15.3 to 29.2 months) versu

59 sudden cardiac death were presyncope (61%), syncope (31%), previous cardiac arrest (14%), ventricula

60 % versus 5.5%, P=0.0006), greater history of syncope (32% versus 17%, P=0.020), and higher rate of su

61 y incontinence (18.5% vs 3.9%; P = .04), and syncope (37% vs 9.6%; P = .01) did not hold up after cor

62 ccessfully clamped at baseline levels at pre-syncope (38.3 +/- 2.7 vs. 38.5 +/- 2.5 mmHg respectively

63 acebo group and the 2.5 mg-maximum group was syncope (4% and 1%, respectively).

64 Prior syncope (4.1%), documented arrhythmia (3.4%), and family

65 , 34 400 (95% CI, 31 200-37 600) episodes of syncope, 43 400 (95% CI, 39 400-47 500) serious electrol

66 nted with either cardiac arrest (15, 71%) or syncope (5, 24%) at an average age of 3 years.

67 ing tachycardia, and these patients had more syncope (5/11 [45%] versus 0/15 [0%]; P<0.01), slower or

68 ntrols, patients with DAPs had more frequent syncope (5/26 [19%] versus 3/73 [4%]; P=0.02) and ventri

69 Patients with MPE more often presented with syncope (59.1% [26 of 44] vs. 25.0% [23 of 92]; p = 0.00

70 55% female) who had undergone stress MPI for syncope; 659 patients (94%) had normal perfusion.

71 cated (preoperative evaluation, 63% vs. 37%; syncope, 69% vs. 31%; P < 0.001 for each).

72 53%), 25 were preoperatively symptomatic (15 syncope, 7 near-drowning, and 3 resuscitated sudden deat

73 730, 69.7%), except for higher frequency of syncope (9.2%) in the OH+ placebo arm.

74 Nonsustained ventricular tachycardia, syncope, a family history of sudden cardiac death, and s

75 ) increased hazard of a composite of cardiac syncope, aborted cardiac arrest, and sudden cardiac deat

76 ith a 1% to 5% annual risk of LQTS-triggered syncope, aborted cardiac arrest, or sudden cardiac death

77 etine prevents arrhythmic events (arrhythmic syncope, aborted cardiac arrest, or sudden cardiac death

78 tive in reducing the risk of cardiac events (syncope, aborted cardiac arrest, sudden cardiac death).

79 ge: 34.0+/-13.8 years) with cardioinhibitory syncope, advanced atrioventricular block or sinus arrest

80 severity AEs were reported in two subjects; syncope after a single 250 mg dose (one subject) and abd

81 The first admission for syncope among healthy individuals significantly predicts

82 PE seems to be a rather uncommon cause of syncope among patients presenting to the ED.

83 ,017 patients with a first-time diagnosis of syncope and 185,085 control subjects; their median age w

84 We defined 3 stages before syncope and 2 after it based on direction changes of the

85 ope beyond patients with recurrent vasovagal syncope and asystole documented by implantable loop reco

86 efit of pacing among patients with recurrent syncope and asystole documented by implantable loop reco

87 collected baseline characteristics, time of syncope and ED arrival, and the Canadian Syncope Risk Sc

88 tentially life-threatening symptoms, such as syncope and end-stage organ hypoperfusion.

89 Prior syncope and family history of sudden death are predictor

90 2.7%) who had an alternative explanation for syncope and in 52 of the 205 patients (25.4%) who did no

91 2 class IIa recommendations, LVEF >35% with syncope and LVEF >35% with inducible ventricular arrhyth

92 inostat 160 mg twice daily: one (2%) grade 3 syncope and one (2%) grade 3 myalgia event in different

93 re, whether pacing reduces risk of recurrent syncope and relevant clinical outcomes among adult patie

94 dered during the evaluation of syncope, near-syncope and seizures, especially in the setting of exerc

95 ith long QT syndrome type 1, which can cause syncope and sudden cardiac death.

96 S) is an arrhythmogenic disorder that causes syncope and sudden death.

97 2%) and 14,251 (7.1%) deaths occurred in the syncope and the control population, respectively, yieldi

98 n as the start of an HR decrease (HR) before syncope and used logarithms of SV, HR, and TPR ratios to

99 remained asymptomatic, 39 (11.2%) developed syncope, and 32 (9.2%) developed VF/SCD.

100 diac arrest survivors, 27 had presented with syncope, and 59 were asymptomatic.

101 gia, bone pain, generalised muscle weakness, syncope, and dyspnea.

102 decline but are associated with hypotension, syncope, and greater medication burden.

103 Angina, exertional syncope, and heart failure are key symptoms indicating a

104 4%, and 61% of patients with cardiac arrest, syncope, and no symptoms, respectively.

105 oventricular block, presenting clinically as syncope, and sudden death.

106 d observational studies examining pacing and syncope, and the bibliographies of known systematic revi

107 Cardiac syncope, as adjudicated by two physicians based on all i

108 The diagnostic accuracy for cardiac syncope, as quantified by the area under the curve (AUC)

109 =16 years old) presenting within 24 hours of syncope at 6 EDs.

110 lass, family history of sudden death (FHSD), syncope, atrial fibrillation, non-sustained ventricular

111 leads to paroxysmal dizziness, fatigue, and syncope because of a temporarily or permanently reduced

112 upport the use of pacing for reflex-mediated syncope beyond patients with recurrent vasovagal syncope

113 DDD-CLS pacing significantly reduced syncope burden and time to first recurrence by 7-fold, p

114 diate- to high-risk patients presenting with syncope but not for low-risk patients.

115 ow promising diagnostic accuracy for cardiac syncope, but diagnostic thresholds require validation.

116 portion of patients with recurrent vasovagal syncope by at least 40%, representing a pre-specified mi

117 ortisone reduced the likelihood of vasovagal syncope by the specified risk reduction of 40%.

118 Syncope can result from a reduction in cardiac output fr

119 s who experienced recurrent exertion-induced syncope/cardiac arrest beginning at 1 year of age.

120 ding heart failure, infarction, arrhythmias, syncope, cardiomyopathy, angina, heart transplantation a

121 ars with head-up tilt test-induced vasovagal syncope compared with sham pacing.

122 toms (headache, numbness, weakness, vertigo, syncope, diplopia, hypotension, floaters, other).

123 ne plasmatic level define a distinct form of syncope, distinguish it from VVS, and suggest a causal r

124 in 163 patients with tilt-induced vasovagal syncope documented by continuous ECG and video EEG monit

125 AF to the risk of cardiac events defined as syncope, documented torsades de pointes, and aborted car

126 ther at rest or induced by hypocapnia at pre-syncope does not impact OT, probably due to a compensato

127 systematic PE-screening in all patients with syncope does not seem warranted.

128 the PENFS group, two in the sham group), and syncope due to needle phobia (n=1; in the sham group).

129 Orthostatic hypotension, syncope, dyskinesia, hallucinations, prolongation of the

130 es of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney inj

131 nd (ii) serious adverse events (hypotension, syncope, electrolyte abnormalities, bradycardia, or acut

132 ower-body negative pressure (LBNP) until pre-syncope; end-tidal carbon dioxide (P ET , CO 2) was clam

133 (BAsel Syncope EvaLuation Study [BASEL IX]; NCT01548352).

134 (HR: 1.74; 95% CI: 1.68 to 1.80), recurrent syncope event rate of 45.1 per 1,000, stroke event rate

135 , and 10 757 (49.5%) employed at time of the syncope event.

136 examined for their relationships with ictal syncope events.

137 -up of 72+/-95 months, all patients remained syncope free.

138 ociety class 3 to 4 from 26% to 2%; and with syncope from 25% to 2%.

139 h patients age >/=40 years, with high burden syncope (>/=5 episodes, >/=2 episodes in the past year),

140 he Heart Rhythm Society, published its first syncope guidelines in 2017.

141 diology released the fourth iteration of its syncope guidelines in 2018.

142 o third quartiles, 2.0-4.5), 622 people with syncope had an occupational accident requiring hospitali

143 Several studies suggest that vasovagal syncope has a genetic origin, but this is unclear.

144 syndrome and aborted sudden cardiac death or syncope have higher risks for ventricular arrhythmias (V

145 risk of LAE was associated with a history of syncope (hazard ratio [HR]: 4.54; p = 0.02), with the do

146 able analysis, type 1 electrocardiogram with syncope (hazard ratio: 4.96; 95% confidence interval: 1.

147 outcome included previous cardiac arrest or syncope (hazard ratio=3.4; 95% confidence interval, 1.4-

148 0.97-3.09]), 3.0% vs 2.4%, respectively, for syncope (HR, 1.23 [95% CI, 0.76-2.00]), 4.0% vs 2.7% for

149 sone significantly reduced the likelihood of syncope (HR: 0.63; 95% CI: 0.42 to 0.94; p = 0.024).

150 lation (hazard ratio [HR]: 4.38; p = 0.002), syncope (HR: 3.36; p < 0.001), participation in strenuou

151 rs of severe anaphylaxis were defined as (1) syncope, hypotension, or hypoxia; (2) signs and symptoms

152 nts, cognitive impairment, fractures, falls, syncope, hypotension, withdrawals due to adverse events,

153 302 patients with anaphylaxis, 55 (18%) had syncope, hypoxia, or hypotension, 57 (19%) required hosp

154 should be considered in patients with ictal syncope if they are not considered good candidates for e

155 sudden cardiac death in 6 patients (24%) and syncope in 4 patients (16%).

156 ts without previous comorbidity admitted for syncope in Denmark from 2001 to 2009 were identified in

157 MT c.472 A alleles associated with decreased syncope in males but increased in females ( P=0.017).

158 promoter L alleles associated with decreased syncope in males but increased in females ( P=0.059).

159 , the HTR1A(-1019) G alleles associated with syncope in males, but not in females ( P=0.005).

160 he yield of stress MPI for the evaluation of syncope in patients at risk but without known coronary a

161 The presence of syncope in patients with aortic valve stenosis (AS) pred

162 is, only Zva was an independent predictor of syncope in patients with AS (odds ratio, 2.02; 95% confi

163 per m(2) as the cutoff value associated with syncope in patients with AS.

164 Syncope in patients with bifascicular block (BFB) is a c

165 cing was effective in reducing recurrence of syncope in patients with presumed neurally mediated sync

166 Stress MPI for evaluation of syncope in patients without known coronary artery diseas

167 was a marginally nonsignificant reduction in syncope in the fludrocortisone group (hazard ratio [HR]:

168 ailure (in 3% of patients in each group) and syncope (in 2% of the riociguat group and in 3% of the p

169 Syncope is a common clinical event, but knowledge of pro

170 Syncope is a commonly encountered and challenging proble

171 Syncope is a sudden transient loss of consciousness and

172 ons for diagnosis and risk-stratification of syncope is incompletely understood.

173 Ictal syncope is more common in left than in right temporal se

174 ary embolism among patients hospitalized for syncope is not well documented, and current guidelines p

175 r emergency department (ED) presentation for syncope is poorly described.

176 drocortisone for the prevention of vasovagal syncope; ISRCTN51802652; Prevention of Syncope Trial 2 [

177 The GG and AA males had 50% and 15% syncope likelihoods, whereas females had 52% and 73% syn

178 The LL and SS males had 25% and 47% syncope likelihoods, whereas females had 75% and 50% syn

179 likelihoods, whereas females had 52% and 73% syncope likelihoods.

180 likelihoods, whereas females had 75% and 50% syncope likelihoods.

181 tatus; extent of structural disease; cardiac syncope; male sex; the presence of multiple mutations or

182 ears) and had a history of fewer episodes of syncope (median of 2 [interquartile range [IQR]: 1 to 2.

183 rawn postapproval after visual disturbances, syncope, myasthenia gravis, and hepatotoxicity were note

184 Mood changes after syncope (n = 323; sensitivity, 3% [95% CI, 0%-7%]; speci

185 and inability to remember behavior prior to syncope (n = 323; sensitivity, 5% [95% CI, 0%-9%]; speci

186 associated with higher likelihood of cardiac syncope (n = 323; sensitivity, 8% [95% CI, 2%-14%]; spec

187 ssociated with greater likelihood of cardiac syncope (n = 323; sensitivity, 91% [95% CI, 85%-97%]; sp

188 Eleven studies of cardiac syncope (N = 4317) were included.

189 associated with lower likelihood of cardiac syncope (n = 456; range of sensitivity, 89%-91%, range o

190 epsis (n=2 [4%]), abdominal pain (n=1 [2%]), syncope (n=1 [2%]), cellulitis (n=1 [2%]), pneumonitis (

191 All cases of recurrent syncope (n=12) were attributed to a vasovagal (n=10) or

192 Patients with syncope (n=79; 18%) had higher Zva (5.1+/-0.9 versus 4.4

193 hould be considered during the evaluation of syncope, near-syncope and seizures, especially in the se

194 in patients with presumed neurally mediated syncope (NMS) and documented asystole but syncope still

195 , she experienced two additional episodes of syncope not related to exercise.

196 events and could be helpful in investigating syncope not related to VAs.

197 atients in the placebo group (P = 0.12), and syncope occurred in 4.0% of the patients in the vericigu

198 Whenever syncope occurs despite optimal medical therapy, LCSD cou

199 Prior syncope (odds ratio, 4.0; 95% confidence interval, 1.6-9

200 Age at first syncope of at least 35 years was associated with greater

201 18 patients (22%) and anemia, headache, and syncope of grade 3 or higher each occurred in 2 patients

202 In the Third International Study on Syncope of Uncertain Etiology (ISSUE-3), cardiac pacing

203 linded ISSUE-3 (Third International Study on Syncope of Uncertain Etiology) trial, which demonstrated

204 ents in patients with bifascicular block and syncope of undetermined origin implanted with permanent

205 In patients with bifascicular block and syncope of undetermined origin, the use of a dual chambe

206 ad an aborted cardiac arrest, 2 patients had syncope only, 10 patients had >/=1 appropriate ICD disch

207 uals with these disorders often present with syncope or a life-threatening arrhythmic episode.

208 Age of onset of major symptoms (syncope or cardiac arrest) ranged from 1 to 9 years.

209 A history of unexplained syncope or of documented sustained ventricular tachycard

210 syncope), or other causes, such as vasovagal syncope or orthostatic hypotension.

211 Innocent murmur and syncope or palpitations with no other indications of car

212 The most common problems were syncope or presyncope (37.4% of cases), respiratory symp

213 She denied experiencing fevers, syncope or presyncope, focal neurologic deficits, chest

214 nts (BCEs) were defined as LQTS-attributable syncope or seizures, aborted cardiac arrest, appropriate

215 d to DDD60 led to a significant reduction of syncope or symptomatic events associated with a cardioin

216 with sustained ventricular tachycardia with syncope or systolic heart failure as a result of ischemi

217 y of anxiety (OR 1.90, 95% CI:1.12-3.24) and syncope (OR 2.75, 95% CI:1.45-5.22).

218 ythmias or structural heart disease (cardiac syncope), or other causes, such as vasovagal syncope or

219 ute coronary syndromes, cardiac arrhythmias, syncope, or even sudden cardiac death.

220 the effects of fludrocortisone in vasovagal syncope over a 1-year treatment period.

221 hest pain, 2 dyspnea, 1 heart failure, and 1 syncope) over 368+/-156 days follow-up.

222 Syncope (P<0.001), cardiac arrest (P<0.001), and treatme

223 f seizures with asystole duration>6 s led to syncope (P=0.02).

224 adian Cardiology Society class (P=0.106), or syncope (P=0.426) after ASA.

225 Atrial fibrillation, syncope, participation in strenuous exercise after the d

226 recorded cardiopulmonary dynamics in supine syncope patients and healthy volunteers (aged 15-27 year

227 ac pacing was effective in neurally mediated syncope patients with documented asystolic episodes in w

228 of the following: chest/abdominal/back pain, syncope, perfusion deficit, and if AAS was in the differ

229 rade 3 increased aspartate aminotransferase, syncope, pericardial effusion, and hyperkalaemia, and gr

230 is, the incidence rate ratio in the employed syncope population was higher than in the employed gener

231 e of 14.3 per 1,000 person-years (PY) in the syncope population.

232 Characterization of ictal syncope predictors may aid in the selection of high-risk

233 est requiring resuscitation (1 death), 5 had syncope/presyncope, and 2 were asymptomatic.

234 artment visits, atrial fibrillation/flutter, syncope/presyncope, end-stage liver disease, malignancy,

235 Routine use of NT-proBNP for ED syncope prognostication is not recommended.

236 Of these, 3 events-syncope, pulmonary embolism, and serum creatinine increa

237 symptoms (palpitations, fatigue, and [near-]syncope), PVC burden on 24-hour Holter, NT-proBNP levels

238 tors of RV pathology included the following: syncope; Q waves or precordial QRS amplitudes <1.8 mV; 3

239 ent-years; HR, 0.87; P = .50) and arrhythmic syncope rates (3.1 [95% CI, 2.6-4.6] vs 1.9 [95% CI, 1.1

240 and 26 TT-) with asystolic neurally mediated syncope received a pacemaker.

241 Syncope recurred in 8 TT+ and in 1 TT- patients.

242 currence by 7-fold, prolonging time to first syncope recurrence in patients age >/=40 years with head

243 At 21 months, the estimated product-limit syncope recurrence rates were 55% and 5%, respectively (

244 ly 14 patients were lost to follow-up before syncope recurrence.

245 Of these, 96 patients had >/=1 syncope recurrences, and only 14 patients were lost to f

246 11 hospitals in Italy for a first episode of syncope, regardless of whether there were alternative ex

247 associated with a 70% reduction in recurrent syncope (relative risk [RR]: 0.30; 95% confidence interv

248 cm s(-1) (31%; P </= 0.001), but time to pre-syncope remained similar between trials (placebo: 1123 +

249 Pacing in vasovagal syncope remains controversial.

250 n-flight medical emergencies were related to syncope, respiratory symptoms, or gastrointestinal sympt

251 of syncope and ED arrival, and the Canadian Syncope Risk Score (CSRS) risk category.

252 n Fransisco Syncope Rule (SFSR) and Canadian Syncope Risk Score (CSRS) served as the prognostic compa

253 The ROSE, OESIL, San Fransisco Syncope Rule (SFSR) and Canadian Syncope Risk Score (CSR

254 e diagnosis was ascertained with the Calgary Syncope Score.

255 er defibrillator shock or (2) arrhythmogenic syncope, seizures, or aborted cardiac arrest after LCSD.

256 Long-QT syndrome (LQTS) may result in syncope, seizures, or sudden cardiac arrest.

257 stained ventricular tachycardia, unexplained syncope, septal diameter z-score, left ventricular poste

258 ggest that the term vasodepression in reflex syncope should not be limited to reduced arterial vasoco

259 who experienced episodes of exertion-induced syncope since age 10, had normal QT interval, and displa

260 (Closed Loop Stimulation for Neuromediated Syncope [SPAIN Study]; NCT01621464).

261 The EGSYS, a syncope-specific diagnostic score, served as the diagnos

262 ed syncope (NMS) and documented asystole but syncope still recurred in 25% of them at 2 years.

263 he multivariable Evaluation of Guidelines in Syncope Study (EGSYS) score, which is based on 6 clinica

264 alleles of serotonin signaling and vasovagal syncope, supporting the serotonin hypothesis of the phys

265 At syncope, SV and HR contributed similarly to the BP decre

266 atients had >2 syncopal spells and a Calgary Syncope Symptom Score >-3.

267 ain, nonspecific pain, headache, hypotension/syncope, tachycardia (including postural orthostatic tac

268 Symptoms prior to syncope that were associated with lower likelihood of ca

269 ), pulmonary toxic effects (six [24%] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%]

270 Prevention of syncope through permanent cardiac pacing in patients wit

271 Unselected patients presenting with syncope to the ED were prospectively enrolled in a diagn

272 Among 1,397 patients presenting with syncope to the ED, PE was detected at presentation in 19

273 tic PE screening in patients presenting with syncope to the ED.

274 sments, in patients >45years presenting with syncope to the emergency department (ED) in a prospectiv

275 ry embolism (PE) in patients presenting with syncope to the emergency department (ED) is largely unkn

276 vagal syncope; ISRCTN51802652; Prevention of Syncope Trial 2 [POST 2]; NCT00118482).

277 The multicenter POST 2 (Prevention of Syncope Trial 2) was a randomized, placebo-controlled, d

278 e evaluation vignettes and 82% to 85% of the syncope vignettes.

279 hs-cTnI were significantly higher in cardiac syncope vs. other causes (p<0.01).

280 l tachycardia syndrome (POTS), and vasovagal syncope (VVS), symptomatic excessive HR occurs.

281 recovery; the most common form is vasovagal syncope (VVS).

282 se of 31 patients with established vasovagal syncope (VVS).

283 In this nationwide cohort, syncope was associated with a 1.4-fold higher risk of oc

284 the uncontrolled trial, yet the time to pre-syncope was comparable between trials (544 +/- 130 vs. 5

285 ly diagnosed heart failure, arrhythmias, and syncope was generally found to be Appropriate or May Be

286 Syncope was more common with left temporal (40%) than wi

287 No significant difference in the risk of syncope was observed with conventional versus therapy re

288 n the uncontrolled trial, P ET , CO 2 at pre-syncope was reduced by 10.9 +/- 3.9 mmHg (P </= 0.001).

289 eligible for diagnostic assessment, cardiac syncope was the adjudicated diagnosis in 234 patients (1

290 p, and 3.4% in the placebo group; those with syncope were 1.5%, 0.8%, and 0.4%, respectively.

291 Falls, with or without injury, and syncope were comparable in the treatment groups.

292 duals, 21 729 with a first-time diagnosis of syncope were identified, with a median age 48.4 years (f

293 associated with lower likelihood of cardiac syncope were mood change or prodromal preoccupation with

294 Data on falls and syncope were not available.

295 actors lowering BP in tilt-induced vasovagal syncope were reduced SV and cardioinhibition.

296 seizure with asystole duration</=6 s led to syncope, whereas 94% (15/16) of seizures with asystole d

297 generally much higher among ED patients with syncope who had a 30-day SAE, this blood test added litt

298 We examined the associations of syncope with occupational accidents and termination of e

299 ry findings of 15 patients with sudden-onset syncope without prodromes who had a normal heart and nor

300 indings of patients affected by sudden-onset syncope without prodromes who had a normal heart and nor